We believe that our close relationship with Micropore has increased the likelihood of successful clinical and commercial production of a variety of microsphere drugs under development, including our innovative one-month long acting Alzheimer’s drug
Heeyong Lee, G2GBIO’s CEO.
Micropore has just announced a Licence Agreement with South Korea based G2GBIO Inc to deploy its patented membrane technology, for the manufacture of G2GBIO’s sustained release pharmaceutical products. G2GBIO specialises in the development of long-acting microsphere products. Micropore’s membrane-based encapsulation system will complement G2GBIO’s existing InnoLAMP technology for the manufacture of monodisperse microspheres composed of various polymers for long-acting drugs for the treatment of various medical conditions such as central nervous system diseases, including dementia or schizophrenia, and chronic diseases, such as cancer and diabetes. Micropore’s technology will allow G2GBIO to further scale up GMP production of its encapsulated products enabling the manufacture of 1kg/hour of emulsion with precisely uniform particle sizes. This throughput equates to 1,000 vials for Alzheimer’s disease treatment or about 30,000 vials for animal neutering drugs. According to G2G Bio, no other company in South Korea can currently achieve these scales of production. Today’s news follows an announcement earlier this year of a similar licensing agreement between Micropore Technologies and Netherlands-based pharmaceutical producer InnoCore Technologies.